<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37759493</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>18</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Biomarkers of Neurological Damage: From Acute Stage to Post-Acute Sequelae of COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2270</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12182270</ELocationID><Abstract><AbstractText><b>Background</b>: Neurological symptoms (NS) in COVID-19 are related to both acute stage and long-COVID. We explored levels of brain injury biomarkers (NfL and GFAP) and myeloid activation marker (sCD163) and their implications on the CNS. <b>Materials and Methods:</b> In hospitalized COVID-19 patients plasma samples were collected at two time points: on hospital admission (baseline) and three months after hospital discharge (Tpost). Patients were stratified according to COVID-19 severity based on acute respiratory distress syndrome (ARDS) onset (severe and non-severe groups). A further stratification according to the presence of NS (with and without groups) at baseline (requiring a puncture lumbar for diagnostic purposes) and according to NS self-referred at Tpost was performed. Finally, cerebrospinal fluid (CSF) samples were collected from patients with NS present at baseline. <b>Results:</b> We enrolled 144 COVID-19 patients (62 female/82 male; median age [interquartile range, IQR]): 64 [55-77]) and 53 heathy donors (HD, 30 female/23 male; median age [IQR]: 64 [59-69]). At baseline, higher plasma levels of NfL, GFAP and sCD163 in COVID-19 patients compared to HD were observed (<i>p</i> &lt; 0.0001, <i>p</i> &lt; 0.0001 and <i>p</i> &lt; 0.0001, respectively), especially in those with severe COVID-19 (<i>p</i> &lt; 0.0001, <i>p</i> &lt; 0.0001 and <i>p</i> &lt; 0.0001, respectively). Patients with NS showed higher plasma levels of NfL, GFAP and sCD163 compared to those without (<i>p</i> = 0.0023, <i>p</i> &lt; 0.0001 and 0.0370, respectively). At baseline, in COVID-19 patients with NS, positive correlations between CSF levels of sCD163 and CSF levels of NfL (&#x3c1; = 0.7536, <i>p</i> = 0.0017) and GFAP were observed (&#x3c1; = 0.7036, <i>p</i> = 0.0045). At Tpost, the longitudinal evaluation performed on 77 COVID-19 patients showed a significant reduction in plasma levels of NfL, GFAP and sCD163 compared to baseline (<i>p</i> &lt; 0.0001, <i>p</i> &lt; 0.0001 and <i>p</i> = 0.0413, respectively). Finally, at Tpost, in the severe group, higher plasma levels of sCD163 in patients with NS compared to those without were reported (<i>p</i> &lt; 0.0001). <b>Conclusions:</b> High plasma levels of NfL, GFAP and sCD163 could be due to a proinflammatory systemic and brain response involving microglial activation and subsequent CNS damage. Our data highlight the association between myeloid activation and CNS perturbations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zingaropoli</LastName><ForeName>Maria Antonella</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasculli</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6678-6865</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbato</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1737-9064</Identifier><AffiliationInfo><Affiliation>Department of Sense Organs, Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR), Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrella</LastName><ForeName>Carla</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0651-1816</Identifier><AffiliationInfo><Affiliation>Department of Sense Organs, Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR), Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiore</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6806-9715</Identifier><AffiliationInfo><Affiliation>Department of Sense Organs, Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR), Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dominelli</LastName><ForeName>Federica</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8059-5088</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latronico</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6971-5416</Identifier><AffiliationInfo><Affiliation>Department of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, 70121 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciccone</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonacci</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liuzzi</LastName><ForeName>Grazia Maria</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0001-5692-9335</Identifier><AffiliationInfo><Affiliation>Department of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, 70121 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talarico</LastName><ForeName>Giuseppina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Human Neuroscience, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruno</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Human Neuroscience, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galardo</LastName><ForeName>Gioacchino</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Emergency Unit, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugliese</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8076-1250</Identifier><AffiliationInfo><Affiliation>Department of Specialist Surgery and Organ Transplantation "Paride Stefanini", Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichtner</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7730-3953</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, 00185 Latina, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Mental Health, and Sense Organs, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastroianni</LastName><ForeName>Claudio Maria</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-1286-467X</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minni</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Sensory Organs, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Otolaryngology-Head and Neck Surgery, ASL Rieti-Sapienza University, Ospedale San Camillo de Lellis, Viale Kennedy, 02100 Rieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciardi</LastName><ForeName>Maria Rosa</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GFAP</Keyword><Keyword MajorTopicYN="N">NfL</Keyword><Keyword MajorTopicYN="N">central nervous system</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">glial fibrillary acidic protein</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">neuro-COVID</Keyword><Keyword MajorTopicYN="N">neurofilament light chain</Keyword><Keyword MajorTopicYN="N">sCD163</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37759493</ArticleId><ArticleId IdType="pmc">PMC10526816</ArticleId><ArticleId IdType="doi">10.3390/cells12182270</ArticleId><ArticleId IdType="pii">cells12182270</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324:782&#x2013;793. doi: 10.1001/jama.2020.12839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zingaropoli M.A., Iannetta M., Piermatteo L., Pasculli P., Latronico T., Mazzuti L., Campogiani L., Duca L., Ferraguti G., De Michele M., et al. Neuro-Axonal Damage and Alteration of Blood-Brain Barrier Integrity in COVID-19 Patients. Cells. 2022;11:2480. doi: 10.3390/cells11162480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11162480</ArticleId><ArticleId IdType="pmc">PMC9406414</ArticleId><ArticleId IdType="pubmed">36010557</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordvig A.S., Fong K.T., Willey J.Z., Thakur K.T., Boehme A.K., Vargas W.S., Smith C.J., Elkind M.S.V. Potential Neurologic Manifestations of COVID-19. Neurol. Clin. Pract. 2021;11:e135&#x2013;e146. doi: 10.1212/CPJ.0000000000000897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000897</ArticleId><ArticleId IdType="pmc">PMC8032406</ArticleId><ArticleId IdType="pubmed">33842082</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T. Neurological Infection with SARS-CoV-2&#x2014;The Story so Far. Nat. Rev. Neurol. 2021;17:65&#x2013;66. doi: 10.1038/s41582-020-00453-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00453-w</ArticleId><ArticleId IdType="pmc">PMC7789883</ArticleId><ArticleId IdType="pubmed">33414554</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarraj J., Park E.S., Colpo G.D., Hinds S.N., Morales D., Ahnstedt H., Paz A.S., Assing A., Liu F., Juneja S., et al. Brain Injury, Endothelial Injury and Inflammatory Markers Are Elevated and Express Sex-Specific Alterations after COVID-19. J. Neuroinflamm. 2021;18:277. doi: 10.1186/s12974-021-02323-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02323-8</ArticleId><ArticleId IdType="pmc">PMC8627162</ArticleId><ArticleId IdType="pubmed">34838058</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriguchi T., Harii N., Goto J., Harada D., Sugawara H., Takamino J., Ueno M., Sakata H., Kondo K., Myose N., et al. A First Case of Meningitis/Encephalitis Associated with SARS-Coronavirus-2. Int. J. Infect. Dis. 2020;94:55&#x2013;58. doi: 10.1016/j.ijid.2020.03.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.03.062</ArticleId><ArticleId IdType="pmc">PMC7195378</ArticleId><ArticleId IdType="pubmed">32251791</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J., Kremer S., Merdji H., Clere-Jehl R., Schenck M., Kummerlen C., Collange O., Boulay C., Fafi-Kremer S., Ohana M., et al. Neurologic Features in Severe SARS-CoV-2 Infection. N. Engl. J. Med. 2020;382:2268&#x2013;2270. doi: 10.1056/NEJMc2008597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2008597</ArticleId><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L., Jin H., Wang M., Hu Y., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683&#x2013;690. doi: 10.1001/jamaneurol.2020.1127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul M.A., Benjamin L., Singh B., Lant S., Michael B.D., Easton A., Kneen R., Defres S., Sejvar J., Solomon T. Neurological Associations of COVID-19. Lancet Neurol. 2020;19:767&#x2013;783. doi: 10.1016/S1474-4422(20)30221-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30221-0</ArticleId><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Premraj L., Kannapadi N.V., Briggs J., Seal S.M., Battaglini D., Fanning J., Suen J., Robba C., Fraser J., Cho S.-M. Mid and Long-Term Neurological and Neuropsychiatric Manifestations of Post-COVID-19 Syndrome: A Meta-Analysis. J. Neurol. Sci. 2022;434:120162. doi: 10.1016/j.jns.2022.120162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120162</ArticleId><ArticleId IdType="pmc">PMC8798975</ArticleId><ArticleId IdType="pubmed">35121209</ArticleId></ArticleIdList></Reference><Reference><Citation>Liotta E.M., Batra A., Clark J.R., Shlobin N.A., Hoffman S.C., Orban Z.S., Koralnik I.J. Frequent Neurologic Manifestations and Encephalopathy-Associated Morbidity in COVID-19 Patients. Ann. Clin. Transl. Neurol. 2020;7:2221&#x2013;2230. doi: 10.1002/acn3.51210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51210</ArticleId><ArticleId IdType="pmc">PMC7664279</ArticleId><ArticleId IdType="pubmed">33016619</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcombe V.F.J., Dangayach N.S., Sonneville R. Neurological Complications of COVID-19. Intensive Care Med. 2021;47:1021&#x2013;1023. doi: 10.1007/s00134-021-06439-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06439-6</ArticleId><ArticleId IdType="pmc">PMC8183330</ArticleId><ArticleId IdType="pubmed">34097083</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassin A., Nawaiseh M., Shaban A., Alsherbini K., El-Salem K., Soudah O., Abu-Rub M. Neurological Manifestations and Complications of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis. BMC Neurol. 2021;21:138. doi: 10.1186/s12883-021-02161-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-021-02161-4</ArticleId><ArticleId IdType="pmc">PMC8007661</ArticleId><ArticleId IdType="pubmed">33784985</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur K.T., Miller E.H., Glendinning M.D., Al-Dalahmah O., Banu M.A., Boehme A.K., Boubour A.L., Bruce S.S., Chong A.M., Claassen J., et al. COVID-19 Neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain. 2021;144:2696&#x2013;2708. doi: 10.1093/brain/awab148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab148</ArticleId><ArticleId IdType="pmc">PMC8083258</ArticleId><ArticleId IdType="pubmed">33856027</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia M.A., Barreras P.V., Lewis A., Pinilla G., Sokoll L.J., Kickler T., Mostafa H., Caturegli M., Moghekar A., Fitzgerald K.C., et al. Cerebrospinal Fluid in COVID-19 Neurological Complications: Neuroaxonal Damage, Anti-SARS-Cov-2 Antibodies but No Evidence of Cytokine Storm. J. Neurol. Sci. 2021;427:117517. doi: 10.1016/j.jns.2021.117517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117517</ArticleId><ArticleId IdType="pmc">PMC8166041</ArticleId><ArticleId IdType="pubmed">34090021</ArticleId></ArticleIdList></Reference><Reference><Citation>Virhammar J., N&#xe4;&#xe4;s A., F&#xe4;llmar D., Cunningham J.L., Klang A., Ashton N.J., Jackmann S., Westman G., Frithiof R., Blennow K., et al. Biomarkers for Central Nervous System Injury in Cerebrospinal Fluid Are Elevated in COVID-19 and Associated with Neurological Symptoms and Disease Severity. Eur. J. Neurol. 2021;28:3324&#x2013;3331. doi: 10.1111/ene.14703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14703</ArticleId><ArticleId IdType="pmc">PMC8518988</ArticleId><ArticleId IdType="pubmed">33369818</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzetti S., Ferrari S., Zanzoni S., Alberti D., Braggio M., Carta S., Piraino F., Gabbiani D., Girelli D., Nocini R., et al. Neurological Symptoms and Axonal Damage in COVID-19 Survivors: Are There Sequelae? Immunol. Res. 2021;69:553&#x2013;557. doi: 10.1007/s12026-021-09220-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-021-09220-5</ArticleId><ArticleId IdType="pmc">PMC8346772</ArticleId><ArticleId IdType="pubmed">34363587</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N., Ashton N.J., Andersson L.-M., Yilmaz A., Lindh M., Nilsson S., Price R.W., Blennow K., Zetterberg H., Gissl&#xe9;n M. Neurochemical Evidence of Astrocytic and Neuronal Injury Commonly Found in COVID-19. Neurology. 2020;95:e1754&#x2013;e1759. doi: 10.1212/WNL.0000000000010111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010111</ArticleId><ArticleId IdType="pubmed">32546655</ArticleId></ArticleIdList></Reference><Reference><Citation>Aamodt A.H., H&#xf8;gest&#xf8;l E.A., Popperud T.H., Holter J.C., Dyrhol-Riise A.M., Tonby K., Stiksrud B., Quist-Paulsen E., Berge T., Barratt-Due A., et al. Blood Neurofilament Light Concentration at Admittance: A Potential Prognostic Marker in COVID-19. J. Neurol. 2021;268:3574&#x2013;3583. doi: 10.1007/s00415-021-10517-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10517-6</ArticleId><ArticleId IdType="pmc">PMC7980743</ArticleId><ArticleId IdType="pubmed">33743046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameres M., Brandstetter S., Toncheva A.A., Kabesch M., Leppert D., Kuhle J., Wellmann S. Association of Neuronal Injury Blood Marker Neurofilament Light Chain with Mild-to-Moderate COVID-19. J. Neurol. 2020;267:3476&#x2013;3478. doi: 10.1007/s00415-020-10050-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10050-y</ArticleId><ArticleId IdType="pmc">PMC7345451</ArticleId><ArticleId IdType="pubmed">32647900</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H., Blennow K. Fluid Biomarkers for Mild Traumatic Brain Injury and Related Conditions. Nat. Rev. Neurol. 2016;12:563&#x2013;574. doi: 10.1038/nrneurol.2016.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.127</ArticleId><ArticleId IdType="pubmed">27632903</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni G. Peripheral Blood Neurofilament Light Chain Levels: The Neurologist&#x2019;s C-Reactive Protein? Brain. 2018;141:2235&#x2013;2237. doi: 10.1093/brain/awy200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy200</ArticleId><ArticleId IdType="pubmed">30060019</ArticleId></ArticleIdList></Reference><Reference><Citation>Aamodt W.W., Waligorska T., Shen J., Tropea T.F., Siderowf A., Weintraub D., Grossman M., Irwin D., Wolk D.A., Xie S.X., et al. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. Mov. Disord. 2021;36:2945&#x2013;2950. doi: 10.1002/mds.28779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28779</ArticleId><ArticleId IdType="pmc">PMC8688198</ArticleId><ArticleId IdType="pubmed">34480363</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., Carson W.E., Caligiuri M.A. Human Natural Killer Cells: A Unique Innate Immunoregulatory Role for the CD56(Bright) Subset. Blood. 2001;97:3146&#x2013;3151. doi: 10.1182/blood.v97.10.3146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.v97.10.3146</ArticleId><ArticleId IdType="pubmed">11342442</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lorenzo R., Lor&#xe9; N.I., Finardi A., Mandelli A., Cirillo D.M., Tresoldi C., Benedetti F., Ciceri F., Rovere-Querini P., Comi G., et al. Blood Neurofilament Light Chain and Total Tau Levels at Admission Predict Death in COVID-19 Patients. J. Neurol. 2021;268:4436&#x2013;4442. doi: 10.1007/s00415-021-10595-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10595-6</ArticleId><ArticleId IdType="pmc">PMC8108733</ArticleId><ArticleId IdType="pubmed">33973106</ArticleId></ArticleIdList></Reference><Reference><Citation>Chmielewska N., Szyndler J., Makowska K., Wojtyna D., Maciejak P., P&#x142;a&#x17a;nik A. Looking for Novel, Brain-Derived, Peripheral Biomarkers of Neurological Disorders. Neurol. Neurochir. Pol. 2018;52:318&#x2013;325. doi: 10.1016/j.pjnns.2018.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pjnns.2018.02.002</ArticleId><ArticleId IdType="pubmed">29478670</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunkhorst R., Pfeilschifter W., Foerch C. Astroglial Proteins as Diagnostic Markers of Acute Intracerebral Hemorrhage-Pathophysiological Background and Clinical Findings. Transl. Stroke Res. 2010;1:246&#x2013;251. doi: 10.1007/s12975-010-0040-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12975-010-0040-6</ArticleId><ArticleId IdType="pubmed">24323552</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow S.A., Barres B.A. Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity. 2017;46:957&#x2013;967. doi: 10.1016/j.immuni.2017.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.06.006</ArticleId><ArticleId IdType="pubmed">28636962</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg G.A. Matrix Metalloproteinases in Neuroinflammation. Glia. 2002;39:279&#x2013;291. doi: 10.1002/glia.10108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.10108</ArticleId><ArticleId IdType="pubmed">12203394</ArticleId></ArticleIdList></Reference><Reference><Citation>Rempe R.G., Hartz A.M.S., Bauer B. Matrix Metalloproteinases in the Brain and Blood-Brain Barrier: Versatile Breakers and Makers. J. Cereb. Blood Flow. Metab. 2016;36:1481&#x2013;1507. doi: 10.1177/0271678X16655551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X16655551</ArticleId><ArticleId IdType="pmc">PMC5012524</ArticleId><ArticleId IdType="pubmed">27323783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y., Gao Q., Ma Y., Wang F., Tan X., Song D., Hoo R.L.C., Wang Z., Ge X., Han H., et al. An MMP-9 Exclusive Neutralizing Antibody Attenuates Blood-Brain Barrier Breakdown in Mice with Stroke and Reduces Stroke Patient-Derived MMP-9 Activity. Pharmacol. Res. 2023;190:106720. doi: 10.1016/j.phrs.2023.106720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2023.106720</ArticleId><ArticleId IdType="pubmed">36893823</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadhosayni M., Sadat Mohammadi F., Ezzatifar F., Mahdavi Gorabi A., Khosrojerdi A., Aslani S., Hemmatzadeh M., Yazdani S., Arabi M., Marofi F., et al. Matrix Metalloproteinases Are Involved in the Development of Neurological Complications in Patients with Coronavirus Disease 2019. Int. Immunopharmacol. 2021;100:108076. doi: 10.1016/j.intimp.2021.108076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108076</ArticleId><ArticleId IdType="pmc">PMC8367754</ArticleId><ArticleId IdType="pubmed">34450402</ArticleId></ArticleIdList></Reference><Reference><Citation>Polivka J., Polivka J., Krakorova K., Peterka M., Topolcan O. Current Status of Biomarker Research in Neurology. EPMA J. 2016;7:14. doi: 10.1186/s13167-016-0063-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13167-016-0063-5</ArticleId><ArticleId IdType="pmc">PMC4931703</ArticleId><ArticleId IdType="pubmed">27379174</ArticleId></ArticleIdList></Reference><Reference><Citation>Stilund M., Reuschlein A.-K., Christensen T., M&#xf8;ller H.J., Rasmussen P.V., Petersen T. Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients with Multiple Sclerosis. PLoS ONE. 2014;9:e98588. doi: 10.1371/journal.pone.0098588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098588</ArticleId><ArticleId IdType="pmc">PMC4041861</ArticleId><ArticleId IdType="pubmed">24886843</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissen S.K., Ferreira S.A., Nielsen M.C., Schulte C., Shrivastava K., Hennig D., Etzerodt A., Graversen J.H., Berg D., Maetzler W., et al. Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson&#x2019;s Disease. Mov. Disord. 2021;36:963&#x2013;976. doi: 10.1002/mds.28424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28424</ArticleId><ArticleId IdType="pmc">PMC8247308</ArticleId><ArticleId IdType="pubmed">33332647</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H., Zhang X., Ma J., Liu Z., Qi Y., Fang L., Zheng Y., Cai Z. Circulating Soluble CD163: A Potential Predictor for the Functional Outcome of Acute Ischemic Stroke. Front. Neurol. 2021;12:740420. doi: 10.3389/fneur.2021.740420.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.740420</ArticleId><ArticleId IdType="pmc">PMC8712690</ArticleId><ArticleId IdType="pubmed">34970202</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaee M., Foroutan F., Etemad L., Razban V., Tajbakhsh A., Savardashtaki A. Clinical Utility of Soluble CD163 and Its Diagnostic and Prognostic Value in a Variety of Neurological Disorders. Mini Rev. Med. Chem. 2023;23:1592&#x2013;1607. doi: 10.2174/1389557523666230106120302.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389557523666230106120302</ArticleId><ArticleId IdType="pubmed">36617717</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabriek B.O., Van Haastert E.S., Galea I., Polfliet M.M.J., D&#xf6;pp E.D., Van Den Heuvel M.M., Van Den Berg T.K., De Groot C.J.A., Van Der Valk P., Dijkstra C.D. CD163-Positive Perivascular Macrophages in the Human CNS Express Molecules for Antigen Recognition and Presentation. Glia. 2005;51:297&#x2013;305. doi: 10.1002/glia.20208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20208</ArticleId><ArticleId IdType="pubmed">15846794</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea J., Cruickshank G., Teeling J.L., Boche D., Garland P., Perry V.H., Galea I. The Intrathecal CD163-Haptoglobin-Hemoglobin Scavenging System in Subarachnoid Hemorrhage. J. Neurochem. 2012;121:785&#x2013;792. doi: 10.1111/j.1471-4159.2012.07716.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2012.07716.x</ArticleId><ArticleId IdType="pmc">PMC3412209</ArticleId><ArticleId IdType="pubmed">22380637</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver L.K., Hintz-Goldstein K.A., Pioli P.A., Wardwell K., Qureshi N., Vogel S.N., Guyre P.M. Pivotal Advance: Activation of Cell Surface Toll-like Receptors Causes Shedding of the Hemoglobin Scavenger Receptor CD163. J. Leukoc. Biol. 2006;80:26&#x2013;35. doi: 10.1189/jlb.1205756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1205756</ArticleId><ArticleId IdType="pubmed">16799153</ArticleId></ArticleIdList></Reference><Reference><Citation>Etzerodt A., Maniecki M.B., M&#xf8;ller K., M&#xf8;ller H.J., Moestrup S.K. Tumor Necrosis Factor &#x3b1;-Converting Enzyme (TACE/ADAM17) Mediates Ectodomain Shedding of the Scavenger Receptor CD163. J. Leukoc. Biol. 2010;88:1201&#x2013;1205. doi: 10.1189/jlb.0410235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0410235</ArticleId><ArticleId IdType="pubmed">20807704</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Rial J., Curr&#xe1;s-Tuala M.J., Rivero-Calle I., G&#xf3;mez-Carballa A., Cebey-L&#xf3;pez M., Rodr&#xed;guez-Tenreiro C., Dacosta-Urbieta A., Rivero-Velasco C., Rodr&#xed;guez-N&#xfa;&#xf1;ez N., Trastoy-Pena R., et al. Increased Serum Levels of SCD14 and SCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology. Front. Immunol. 2020;11:560381. doi: 10.3389/fimmu.2020.560381.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.560381</ArticleId><ArticleId IdType="pmc">PMC7538662</ArticleId><ArticleId IdType="pubmed">33072099</ArticleId></ArticleIdList></Reference><Reference><Citation>Zingaropoli M.A., Nijhawan P., Carraro A., Pasculli P., Zuccal&#xe0; P., Perri V., Marocco R., Kertusha B., Siccardi G., Del Borgo C., et al. Increased SCD163 and SCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia. Front. Immunol. 2021;12:627548. doi: 10.3389/fimmu.2021.627548.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.627548</ArticleId><ArticleId IdType="pmc">PMC7993197</ArticleId><ArticleId IdType="pubmed">33777012</ArticleId></ArticleIdList></Reference><Reference><Citation>Marocco R., Carraro A., Zingaropoli M.A., Nijhawan P., Tortellini E., Guardiani M., Mengoni F., Zuccal&#xe0; P., Belvisi V., Kertusha B., et al. Role of Tocilizumab in Down Regulating SCD163 Plasmatic Levels in a Cohort of COVID-19 Patients. Front. Immunol. 2022;13:871592. doi: 10.3389/fimmu.2022.871592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.871592</ArticleId><ArticleId IdType="pmc">PMC9013773</ArticleId><ArticleId IdType="pubmed">35444637</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasculli P., Zingaropoli M.A., Masci G.M., Mazzuti L., Perri V., Paribeni F., Russo G., Arcari G., Iafrate F., Vullo F., et al. Chest Computed Tomography Score, Cycle Threshold Values and Secondary Infection in Predicting COVID-19 Mortality. New Microbiol. 2021;44:145&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">34783349</ArticleId></ArticleIdList></Reference><Reference><Citation>Zingaropoli M.A., Latronico T., Pasculli P., Masci G.M., Merz R., Ciccone F., Dominelli F., Del Borgo C., Lichtner M., Iafrate F., et al. Tissue Inhibitor of Matrix Metalloproteinases-1 (TIMP-1) and Pulmonary Involvement in COVID-19 Pneumonia. Biomolecules. 2023;13:1040. doi: 10.3390/biom13071040.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom13071040</ArticleId><ArticleId IdType="pmc">PMC10377146</ArticleId><ArticleId IdType="pubmed">37509076</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella C., Zingaropoli M.A., Ceci F.M., Pasculli P., Latronico T., Liuzzi G.M., Ciardi M.R., Angeloni A., Ettorre E., Menghi M., et al. COVID-19 Affects Serum Brain-Derived Neurotrophic Factor and Neurofilament Light Chain in Aged Men: Implications for Morbidity and Mortality. Cells. 2023;12:655. doi: 10.3390/cells12040655.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12040655</ArticleId><ArticleId IdType="pmc">PMC9954454</ArticleId><ArticleId IdType="pubmed">36831321</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H.-Y., Neu C., Wickel J., Kuckertz S.L., Coldewey S.M. Neurofilament Light Chain in Patients with COVID-19 and Bacterial Pneumonia. Ann. Neurol. 2021;90:174&#x2013;175. doi: 10.1002/ana.26135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26135</ArticleId><ArticleId IdType="pmc">PMC8222870</ArticleId><ArticleId IdType="pubmed">34036618</ArticleId></ArticleIdList></Reference><Reference><Citation>Geis T., Brandstetter S., Toncheva A.A., Laub O., Leipold G., Wagner R., Kabesch M., Kasser S., Kuhle J., Wellmann S., et al. Serum Neurofilament Light Chain (SNfL) Values in a Large Cross-Sectional Population of Children with Asymptomatic to Moderate COVID-19. J. Neurol. 2021;268:3969&#x2013;3974. doi: 10.1007/s00415-021-10554-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10554-1</ArticleId><ArticleId IdType="pmc">PMC8064423</ArticleId><ArticleId IdType="pubmed">33893540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N., Simr&#xe9;n J., Ed&#xe9;n A., Andersson L.-M., Nilsson S., Ashton N.J., Sundvall P.-D., Nellg&#xe5;rd B., Blennow K., Zetterberg H., et al. Neurochemical Signs of Astrocytic and Neuronal Injury in Acute COVID-19 Normalizes during Long-Term Follow-Up. eBioMedicine. 2021;70:103512. doi: 10.1016/j.ebiom.2021.103512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103512</ArticleId><ArticleId IdType="pmc">PMC8320425</ArticleId><ArticleId IdType="pubmed">34333238</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R., Hert L., De Marchis G.M., Twerenbold R., Kappos L., Naegelin Y., Kuster G.M., Benkert P., Jost J., Maceski A.M., et al. Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Ann. Neurol. 2021;89:610&#x2013;616. doi: 10.1002/ana.26004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26004</ArticleId><ArticleId IdType="pubmed">33377539</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng A., Shah M., Ahmad S.A., Premraj L., Wildi K., Li Bassi G., Pardo C.A., Choi A., Cho S.-M. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells. 2023;12:816. doi: 10.3390/cells12050816.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12050816</ArticleId><ArticleId IdType="pmc">PMC10001044</ArticleId><ArticleId IdType="pubmed">36899952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiraoka A., Horiike N., Akbar S.M.F., Michitaka K., Matsuyama T., Onji M. Soluble CD163 in Patients with Liver Diseases: Very High Levels of Soluble CD163 in Patients with Fulminant Hepatic Failure. J. Gastroenterol. 2005;40:52&#x2013;56. doi: 10.1007/s00535-004-1493-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-004-1493-8</ArticleId><ArticleId IdType="pubmed">15692789</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf8;ller H.J., de Fost M., Aerts H., Hollak C., Moestrup S.K. Plasma Level of the Macrophage-Derived Soluble CD163 Is Increased and Positively Correlates with Severity in Gaucher&#x2019;s Disease. Eur. J. Haematol. 2004;72:135&#x2013;139. doi: 10.1046/j.0902-4441.2003.00193.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0902-4441.2003.00193.x</ArticleId><ArticleId IdType="pubmed">14962251</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajamanickam A., Kumar N.P., Pandiarajan A.N., Selvaraj N., Munisankar S., Renji R.M., Venkatramani V., Murhekar M., Thangaraj J.W.V., Kumar M.S., et al. Dynamic Alterations in Monocyte Numbers, Subset Frequencies and Activation Markers in Acute and Convalescent COVID-19 Individuals. Sci. Rep. 2021;11:20254. doi: 10.1038/s41598-021-99705-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-99705-y</ArticleId><ArticleId IdType="pmc">PMC8511073</ArticleId><ArticleId IdType="pubmed">34642411</ArticleId></ArticleIdList></Reference><Reference><Citation>Etzerodt A., Rasmussen M.R., Svendsen P., Chalaris A., Schwarz J., Galea I., M&#xf8;ller H.J., Moestrup S.K. Structural Basis for Inflammation-Driven Shedding of CD163 Ectodomain and Tumor Necrosis Factor-&#x3b1; in Macrophages. J. Biol. Chem. 2014;289:778&#x2013;788. doi: 10.1074/jbc.M113.520213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.520213</ArticleId><ArticleId IdType="pmc">PMC3887204</ArticleId><ArticleId IdType="pubmed">24275664</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdo T.H., Lentz M.R., Autissier P., Krishnan A., Halpern E., Letendre S., Rosenberg E.S., Ellis R.J., Williams K.C. Soluble CD163 Made by Monocyte/Macrophages Is a Novel Marker of HIV Activity in Early and Chronic Infection Prior to and after Anti-Retroviral Therapy. J. Infect. Dis. 2011;204:154&#x2013;163. doi: 10.1093/infdis/jir214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir214</ArticleId><ArticleId IdType="pmc">PMC3105035</ArticleId><ArticleId IdType="pubmed">21628670</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver J., Miller J.H. Regeneration beyond the Glial Scar. Nat. Rev. Neurosci. 2004;5:146&#x2013;156. doi: 10.1038/nrn1326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1326</ArticleId><ArticleId IdType="pubmed">14735117</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanner I.B., Anderson M.A., Song B., Levine J., Fernandez A., Gray-Thompson Z., Ao Y., Sofroniew M.V. Glial Scar Borders Are Formed by Newly Proliferated, Elongated Astrocytes That Interact to Corral Inflammatory and Fibrotic Cells via STAT3-Dependent Mechanisms after Spinal Cord Injury. J. Neurosci. 2013;33:12870&#x2013;12886. doi: 10.1523/JNEUROSCI.2121-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2121-13.2013</ArticleId><ArticleId IdType="pmc">PMC3728693</ArticleId><ArticleId IdType="pubmed">23904622</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Wu Z.-B., Zhuge Q., Zheng W., Shao B., Wang B., Sun F., Jin K. Glial Scar Formation Occurs in the Human Brain after Ischemic Stroke. Int. J. Med. Sci. 2014;11:344&#x2013;348. doi: 10.7150/ijms.8140.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.8140</ArticleId><ArticleId IdType="pmc">PMC3936028</ArticleId><ArticleId IdType="pubmed">24578611</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H., Ma Y., Jiang L., Mu Z., Jiang Z., Chen X., Wang Y., Yang G.-Y., Zhang Z. Hypoxia Response Element-Regulated MMP-9 Promotes Neurological Recovery via Glial Scar Degradation and Angiogenesis in Delayed Stroke. Mol. Ther. 2017;25:1448&#x2013;1459. doi: 10.1016/j.ymthe.2017.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.03.020</ArticleId><ArticleId IdType="pmc">PMC5474960</ArticleId><ArticleId IdType="pubmed">28396199</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosser D.M., Edwards J.P. Exploring the Full Spectrum of Macrophage Activation. Nat. Rev. Immunol. 2008;8:958&#x2013;969. doi: 10.1038/nri2448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2448</ArticleId><ArticleId IdType="pmc">PMC2724991</ArticleId><ArticleId IdType="pubmed">19029990</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellwardt E., Zipp F. Molecular Mechanisms Linking Neuroinflammation and Neurodegeneration in MS. Exp. Neurol. 2014;262 Pt A:8&#x2013;17. doi: 10.1016/j.expneurol.2014.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.02.006</ArticleId><ArticleId IdType="pubmed">24530639</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C., Kempuraj D. Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID. Cells. 2023;12:688. doi: 10.3390/cells12050688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12050688</ArticleId><ArticleId IdType="pmc">PMC10001285</ArticleId><ArticleId IdType="pubmed">36899824</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A., Chatfield D.A., MPhil A.M., Jolly A., Trender W., Hellyer P.J., Giovane M.D., Newcombe V.F.J., Outtrim J.G., Warne B., et al. Multivariate Profile and Acute-Phase Correlates of Cognitive Deficits in a COVID-19 Hospitalised Cohort. eClinicalMedicine. 2022;47:101417. doi: 10.1016/j.eclinm.2022.101417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101417</ArticleId><ArticleId IdType="pmc">PMC9048584</ArticleId><ArticleId IdType="pubmed">35505938</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>